The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
What happened?
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
Story details
The regulator says Tavneos was approved on the basis of manipulated study data.
Should patients still have access to it?
Why it matters
This story helps build a stronger internal English tech archive around Technology, giving search visitors more reasons to keep browsing the site instead of bouncing after a single headline.